Effectiveness of direct‐acting agents for hepatitis C and liver stiffness changing after sustained virological response
- 7 May 2019
- journal article
- research article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 34 (12) , 2187-2195
Abstract
Background and Aim: Few studies have evaluated sustained virological response (SVR) rates by direct‐acting agents (DAAs) and liver stiffness measurement (LSM) changing post‐SVR in limited‐resource settings. We aimed to describe the effectiveness of DAAs for hepatitis C virus treatment and to assess the changing of LSM post‐SVR.Methods: This retrospective study analyzed data of consecutive hepatitis C virus‐infected patients treated by DAAs from 2015 to 2017 in two tertiary centers in Brazil. SVR rates were reported by intention‐to‐treat and per‐protocol analyses. LSM by transient elastography performed before treatment and post‐SVR was compared, and logistic regression models were performed.Results: Six hundred seventy‐one patients (63% female, 62 years [55–68], 89% genotype 1, 8% HIV co‐infected, and 64% with cirrhosis) were included. Most patients were treated by sofosbuvir/daclatasvir ± ribavirin (74%) and sofosbuvir/simeprevir ± ribavirin (21%). SVR rates (95% confidence interval [CI]) were 94.6% (92.7–96.1) and 97.8% (96.4–98.7) for intention‐to‐treat and per‐protocol analyses, respectively. The leading adverse event was anemia (9.6% [95% CI 7.6–12.1]). Pretreatment and post‐SVR12 LSM were available in 400 patients. LSM had significantly decreased after SVR (13.6 kPa [interquartile range, 10.0–21.6] vs 10.2 kPa [7.0–17.6], P < 0.001). A total of 167 patients (42%) decreased at least 30% of LSM post‐SVR. The absence of type 2 diabetes (odds ratio = 1.52 [95% CI 1.05–2.21], P = 0.028) and presence of platelet count ≥ 150 × 109/mm3 (odds ratio = 1.75 [1.23–2.50], P = 0.002) were independently associated with a significant LSM regression (≥ 30%) post‐SVR.Conclusion: DAAs were highly effective and safe, and LSM significantly decreased after SVR in a real‐life cohort in Brazil. The absence of type 2 diabetes and presence of high platelet count were independently associated with LSM decrease post‐SVR.Keywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (405211/2016‐3)
- Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (Bolsa de Iniciação Científica ‐ 2017/2, 235083)
- Fundação Oswaldo Cruz (Programa de Incentivo à Jovens Pesquisadores INI, 06.19)
This publication has 40 references indexed in Scilit:
- Cost-effectiveness of diagnostic and therapeutic interventions for chronic hepatitis C: a systematic review of model-based analysesBMC Medical Research Methodology, 2018
- Oral Direct-Acting Agent Therapy for Hepatitis C Virus InfectionAnnals of Internal Medicine, 2017
- Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver ComplicationsGastroenterology, 2017
- Transient elastography for the diagnosis of liver fibrosis: a systematic review of economic evaluationsLiver International, 2016
- Follow‐up of patients with chronic hepatitis C and a sustained viral responseLiver International, 2016
- α‐fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological responseJournal of Gastroenterology and Hepatology, 2015
- Chronic hepatitis C and liver fibrosisWorld Journal of Gastroenterology, 2014
- Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis CJournal of Hepatology, 2013
- Noninvasive Tests for Fibrosis and Liver Stiffness Predict 5-Year Outcomes of Patients With Chronic Hepatitis CGastroenterology, 2011
- Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapyHepatology, 2009